佐力藥業(300181.SZ)：實控人俞有強與浙醫健簽署的股份轉讓協議等交易協議已終止
格隆匯 9 月 28日丨佐力藥業(300181.SZ)公佈，公司於近日收到公司控股股東、實際控制人俞有強的函告，獲悉俞有強與浙江省醫療健康集團有限公司(“浙醫健”)簽署的《股份轉讓協議》、《股份轉讓協議補充協議》、《關於放棄浙江佐力藥業股份有限公司股份表決權的承諾函》等交易協議已終止。
2020年3月25日，公司控股股東、實際控制人俞有強與浙醫健簽署了《股份轉讓協議》、《關於放棄浙江佐力藥業股份有限公司股份表決權的承諾函》等交易協議，俞有強擬將其持有的91,293,727股股份(佔公司總股本的15%)分二次轉讓予浙醫健。在俞有強首期將持有的公司4329.68萬股股份轉讓予浙醫健，並且俞有強放棄全部表決權生效後及經浙醫健提名並當選的董事(非俞有強推薦的董事)占上市公司董事會半數以上席位，浙醫健即成為上市公司的控股股東，浙江省國資委將成為上市公司實際控制人；同日，公司與浙醫健簽署了附條件生效的《非公開發行股票認購協議》，擬向浙醫健非公開發行公司股票6086.25萬股(含此數)，每股面值人民幣1.00元的人民幣普通股，公司擬募集資金總額不超過人民幣約2.72億元(含約2.72億元)。浙醫健以現金全額方式認購此次非公開發行的全部股票。
2020年3月27日，俞有強與浙醫健簽署了《股份轉讓協議》補充協議，俞有強將其持有的43,296,821股股份轉讓給浙醫健，並就尚處於限售的47,996,906股股份將來轉讓給浙醫健做了原則性規定。
近日，俞有強先生收到浙醫健關於解除《股份轉讓協議》的通知，浙醫健收到控股股東浙江省旅遊投資集團有限公司（更名前為“浙江省旅遊集團有限責任公司”）轉來的《浙江省國資委關於浙江省醫療健康集團有限公司收購浙江佐力藥業股份有限公司事項的意見》（浙國資產權﹝2020﹞27號)。文件中，浙江省國資委認為浙醫健暫不具備收購公司的條件，未予批准協議收購及認購公司股份事項。鑑於浙江省國資委審核未通過，俞有強與浙醫健簽署的《股份轉讓協議》因未達成生效條件而自動解除，公司與浙醫健簽署的《非公開發行股票認購協議》亦自動解除。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
